Premium
Vilazodone no better than placebo or fluoxetine in multisite RCT; open‐label study finds it safe
Publication year - 2020
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30513
Subject(s) - fluoxetine , placebo , major depressive disorder , randomized controlled trial , depression (economics) , open label , medicine , psychiatry , psychology , alternative medicine , serotonin , economics , receptor , cognition , pathology , macroeconomics
Vilazodone was found not effective for pediatric patients with major depressive disorder (MDD) in a recent study comparing it with placebo and fluoxetine. The same improvements in depression were observed in all three arms.